Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing (EGFR-expressing) Advanced NSCLC.
Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing (EGFR-expressing) Advanced NSCLC.
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.
Inclusion Criteria:
Exclusion Criteria:
Halle-Dölau, Germany
Honh Kong, Hong Kong
Nyiregyháza, Hungary
Zalegerzeg-Pózva, Hungary
Rozzano-Milano, Italy
Nieuwegeln, Netherlands
Posnan, Poland
Nitra-Zobor, Slovakia
Elche Alicante, Spain